Brescia

• A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Th … Ended
  2024-515539-31-00 4 2025-04-01 Alzheimer’s disease dementia
• A Multicenter, Randomized, Placebo-Controlled, Parallel Group Trial on the Safety and Efficacy of Istaroxime for Cardiogenic Shock SCAI Stag … Ended
  2023-507243-11-02 4 2025-01-05 Cardiogenic Shock
• Open-Label Extension of EryDex in A-T (OLE NEAT) Ended
  2024-513618-37-00 5 2024-12-23 Ataxia Telangiectasia (A-T)
• Efficacy and Safety of REL-1017 for Major Depressive Disorder Ended
  2023-507399-27-00 5 2024-12-04 Major Depression
• A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended
  2024-511360-87-00 5 2024-10-02 hidradenitis suppurativa (HS)
• A Continuation Study of Latozinemab in Participants with Neurodegenerative Disease Ended
  2023-506805-20-01 5 2024-09-25 Neurodegenerative Diseases
• A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni … Ended
  2023-505755-40-00 4 2024-08-16 Chronic kidney disease
• Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR Ended
  2023-507667-19-00 3 2024-06-06 Polymyalgia rheumatica (PMR)
• A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on subjects with Ataxia-Te … Ended
  2023-509077-23-00 5 2024-06-03 Ataxia Telangiectasia
• A study to learn how safe starting vericiguat at a dose of 5 milligrams is in participants with chronic heart failure with reduced ejection … Ended
  2023-507682-25-00 4 2024-05-13 Chronic heart failure with reduced ejection fraction
• EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended
  2023-505083-11-01 4 2024-05-07 Alzheimer's Disease
• MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended
  2023-506425-12-00 5 2024-04-17 Uncontrolled and Resistant Hypertension
• A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended
  2023-504678-39-00 4 2024-03-13 Heart Failure
• A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended
  2023-505499-32-00 5 2024-03-08 Uncontrolled hypertension (uTHN) defined as blood pressure that remain
• A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo … Ended
  2023-505910-10-00 4 2024-01-23 Relapsed or Refractory High-Risk Myelodysplastic Syndrome
• A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibul … Ended
  2023-505487-11-00 5 2023-12-21 Actinic Keratosis on the Face or Scalp
• PH2a, VH3739937 Proof-Of-Concept in TN HIV-1 Infected Adults Ended
  2023-505780-37-00 4 2023-12-21 HIV Infections
• BRIGHT - A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug … Ended
  2022-502001-15-00 4 2023-12-05 Acute Ischemic Stroke (AIS)
• A study to test whether BI 765845 helps people who have had a heart attack Ended
  2022-502788-39-00 4 2023-11-27 acute myocardial infarction
• Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2) Ended
  2022-501927-25-00 4 2023-09-29 Large B-Cell Lymphoma (LBCL)
• A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis Ended
  2022-502888-38-00 4 2023-09-25 Atopic dermatitis
• A study to compare the effects and safety of gadoquatrane with an already used available contrast agent for MRI tests in people with any kno … Ended
  2022-501885-24-00 5 2023-09-20 Contrast enhancement in magnetic resonance imaging for assessment of n
• SEER-3: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of … Ended
  2022-502697-16-00 5 2023-08-29 Neurotrophic Keratopathy
• A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and … Ended
  2022-502382-25-00 4 2023-08-24 Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WH

Showing 433–456 of 541 trials